Rathbones Group’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$157K Sell
223,378
-3,469
-2% -$3.24K ﹤0.01% 599
2025
Q4
$352K Sell
226,847
-6,815
-3% -$10.9K ﹤0.01% 498
2025
Q3
$369K Sell
233,662
-3,583
-2% -$6.23K ﹤0.01% 488
2025
Q2
$493K Sell
237,245
-7,396
-3% -$17.9K ﹤0.01% 438
2025
Q1
$661K Sell
244,641
-8,466
-3% -$33.4K ﹤0.01% 373
2024
Q4
$1.03M Hold
253,107
0.01% 334
2024
Q3
$995K Sell
253,107
-9,634
-4% -$40.6K 0.01% 332
2024
Q2
$1.07M Sell
262,741
-20,135
-7% -$86.6K 0.01% 323
2024
Q1
$1.22M Sell
282,876
-18,112
-6% -$85K 0.01% 304
2023
Q4
$1.35M Sell
300,988
-2,730
-0.9% -$10.6K 0.01% 289
2023
Q3
$945K Sell
303,718
-37,603
-11% -$151K 0.01% 320
2023
Q2
$1.52M Sell
341,321
-21,263
-6% -$97.7K 0.01% 221
2023
Q1
$1.75M Sell
362,584
-5,004
-1% -$24.6K 0.02% 217
2022
Q4
$1.93M Sell
367,588
-19,014
-5% -$117K 0.02% 202
2022
Q3
$2.5M Sell
386,602
-10,780
-3% -$60.1K 0.03% 189
2022
Q2
$1.83M Sell
397,382
-10,785
-3% -$53.1K 0.02% 214
2022
Q1
$2.89M Sell
408,167
-19,854
-5% -$136K 0.03% 191
2021
Q4
$4.38M Sell
428,021
-19,267
-4% -$207K 0.04% 166
2021
Q3
$5.43M Buy
+447,288
New +$6.74M 0.06% 153

Other funds holding MXCT

Rathbones Group's MXCT Position: Q1 2026 in Review

Rathbones Group reduced its MaxCyte (MXCT) stake by 1.5% in Q1 2026, selling an estimated $3.24K and leaving 223,378 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #599.

Rathbones Group first reported a position in MXCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $5.43M in Q3 2021. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Rathbones Group held 223,378 shares of MaxCyte worth $157K as of Q1 2026.
  • Rathbones Group sold 3,469 MaxCyte shares in Q1 2026, an estimated $3.24K.
  • MaxCyte made up ﹤0.01% of Rathbones Group's portfolio in Q1 2026, its #599 holding.
  • Rathbones Group first reported a position in MaxCyte in Q3 2021 and has held it in 19 quarters since.
  • Rathbones Group's MaxCyte position peaked at $5.43M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.